At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 15, 2026 at 09:19 ET
Tango Therapeutics announced the appointment of Matthew Gall as Chief Financial Officer, effective April 15, 2026, replacing Daniella Beckman. The company also appointed Jessica Newcomb as principal accounting officer and introduced other leadership changes to support late-stage development of its drug vopimetostat. Gall's employment agreement includes a $540,000 base salary and equity awards.
- Matthew Gall appointed CFO effective April 15, 2026, replacing Daniella Beckman
- Gall's employment agreement includes $540,000 annual base salary and target bonus of 40% of base salary
- Gall to receive stock option for 240,000 shares and 40,000 restricted stock units
- Jessica Newcomb appointed principal accounting officer
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access